Boston Scientific Receives CE Mark For Lotus™ Valve System

Boston Scientific Receives CE Mark ForBoston Scientific Receives CE Mark For Lotus™ Valve System PR Newswire NATICK, Massachusetts, Oct. 28, 2013 - Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Lotus™ Valve System, the company's advanced transcatheter aortic valve replacement (TAVR) technology. This key approval offers a unique and effective new treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement. The Lotus Valve System is immediately available to select centers in Europe, with commercial site expansion accelerating as physicians and centers become fully trained. The Lotus Valve System is designed to provide physicians increased control during implantation and to help provide a more precise, predictable procedure. It is the only aortic valve device that can be assessed in its final position prior to release, while maintaining the ability for the physician to reposition or fully resheath and retrieve the valve. The Lotus Valve System also incorporates a unique Adaptive Seal™ technology designed to minimize aortic regurgitation (leaking), a proven predictor of mortality.